Development of a Scalable Synthetic Process for DG-051B, A First-in-Class Inhibitior of LTA4H
作者:Livia A. Enache、Isaac Kennedy、David W. Sullins、Wei Chen、Dragan Ristic、Glenn L. Stahl、Sergey Dzekhtser、Robert A. Erickson、Changren Yan、Frank W. Muellner、Michael D. Krohn、Jennifer Winger、Vincent Sandanayaka、Jasbir Singh、David E. Zembower、Alex S. Kiselyov
DOI:10.1021/op900231j
日期:2009.11.20
DG-051B is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase H clinical development for the prevention of heart attack. Process optimization led from a linear seven-step synthetic procedure to a convergent four-step manufacturing sequence that has been used to manufacture at 100-kg scale. The entire process can be telescoped due to high conversion reactions, low impurity levels, efficient separations, and a very effective final purification. Two key aspects of the process are: (a) bypassing the isolation of a reactive electrophile by using its aqueous-washed reaction mixture directly into a coupling reaction with a phenoxide nucleophile and (b) modulating the properties of the final product solutions for optimal extraction, purification, and crystallization.